News

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -12.39% and -82.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

The biotech's candidate may treat a great number of illnesses that have one thing in common.

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for Casgevy, the gene therapy it co-commercializes with Vertex Pharmaceuticals. An interesting angle for investors is how Casgevy’s early commercial uptake and growing treated-patient base may influence perceptions of CRISPR Therapeutics’ broader gene-editing platform and revenue potential. With the...

CRISPR Therapeutics AG (CRSP) reached $50.71 at the closing of the latest trading day, reflecting a -2.59% change compared to its last close.

These stocks come with risk, but they also have some exciting long-term growth opportunities.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $52.06, representing a +2.1% change from its previous close.